Effect of an antimicrobial stewardship bundle for patients with Clostridium difficile infection

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 3, 2016, Pages 836-840

  Brumley, Paul E ^a   Malani, Anurag N ^a   Kabara, Jared J ^a   Pisani, Jennifer ^b   Collins, Curtis D ^a  

^a Saint Joseph Mercy Health System   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

AGED; ANTIMICROBIAL THERAPY; ARTICLE; CARE BUNDLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; FEMALE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MORTALITY; QUASI EXPERIMENTAL STUDY; TREATMENT DURATION; ADOLESCENT; ADULT; CHEMICALLY INDUCED; CLOSTRIDIUM INFECTIONS; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG UTILIZATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; ORGANIZATIONAL POLICY; PEPTOCLOSTRIDIUM DIFFICILE; PROTOCOL COMPLIANCE; STANDARDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; NON-RANDOMIZED CONTROLLED TRIALS AS TOPIC; ORGANIZATIONAL POLICY; PATIENT READMISSION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84960834548     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv404     Document Type: Article

References (26)

1. The White House. National Action Plan for Combating Antibiotic-Resistant Bacteria. March 2015. www.whitehouse.gov.
2. Lessa FC, Mu Y, Bamberg WM et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372: 825-34.
3. Dellit TH, Owens RC, McGowan JE et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-77.
4. Takesue Y, Ueda T, Mikamo H et al. Management bundles for candidaemia: the impact of compliance on clinical outcomes. J Antimicrob Chemother 2015; 70: 587-93.
5. Antworth A, Collins CD, Kunapuli A et al. Impact of an antimicrobial stewardship programcomprehensive care bundle on management of candidemia. Pharmacotherapy 2013; 33: 137-43.
6. Levy MM, Dellinger RP, Townsend SR et al. The surviving sepsis campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010; 36: 222-31.
7. Morris AC, Hay AW, Swann DG et al. Reducing ventilator-associated pneumonia in intensive care: impact of implementing a care bundle. Crit Care Med 2011; 39: 2218-24.
8. Schweizer ML, Chiang HY, Septimus E et al. Association of a bundled intervention with surgical site infections among patients undergoing cardiac, hip, or knee surgery. JAMA 2015; 313: 2162-71.
9. Muto CA, BlankMK, Marsh JWet al. Control of an outbreak of infectionwith the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. Clin Infect Dis 2007; 45: 1266-73.
10. Jury LA, Tomas M, Jundrapu S et al. AClostridium difficile infection (CDI) stewardship initiative improves adherence to practice guidelines for management of CDI. Infect Control Hosp Epidemiol 2013; 34: 1222-4.
11. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
12. Bauer MP, Kuijper EJ, Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 1067-79.
13. Toth NR, Chambers RM, Davis SL. Implementation of a care bundle for antimicrobial stewardship. Am J Health Syst Pharm 2010; 67: 746-9.
14. Regal RE, Osta AD, Parekh VI. Interventions to curb the overuse of acidsuppressive medication on an inpatient general medicine service. P T 2010; 35: 86-90.
15. Cowen ME, Czerwinski JL, Posa PJ et al. Implementation of a mortality prediction rule for real-time decision making: feasibility and validity. J Hosp Med 2014; 9: 720-6.
16. Charlson ME, Pompei P, Alex KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
17. Zar FA, Bakkanagari SR, Moorthi KM et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-7.
18. Garey KW, Sethi S, Yadav Y et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008; 70: 298-304.
19. Nair S, Yadav D, Corpuz M et al. Clostridium difficile colitis: factors influencing treatment failure and relapse-a prospective evaluation. Am J Gastroenterol 1998; 93: 1873-6.
20. Kyne L, Warny M, Qamar A et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357: 189-93.
21. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009; 58: 403-10.
22. McFarland LV, Surawicz CM, Rubin M et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999; 20: 43-50.
23. Modena S, Gollamudi S, Friedenberg F. Continuation of antibiotics is associated with failure of metronidazole for Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2006; 40: 49-54.
24. Linsky A, Gupta K, Lawler EV et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010; 170: 772-8.
25. Freedberg DE, Salmasian H, Friedman C et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol 2013; 108: 1794-801.
26. Jacobson BC, Ferris TG, Shea TL et al. Who is using chronic acid suppression and why? Am J Gastroenterol 2003; 98: 51-8.